OrthoPediatrics Corp. KIDS
- Market cap
- $591.1M
- P/E
- 0.0×
Follow KIDS
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | 17.03 | 14.00 | 28.19 | 32.21 | 38.96 | 35.67 | 23.10 | 21.02 | 15.28 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | 23.00 | 39.81 | 47.82 | 55.98 | 73.91 | 61.27 | 53.50 | 35.99 | 27.60 |
High Price
|
|||
| 62 | 69 | 80 | 94 | 116 | 133 | 203 | 247 | 562 | 602 |
Employees
|
|||
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 |
Revenue/Emp
|
|||
| 37 | 46 | 58 | 73 | 71 | 98 | 122 | 149 | 205 | 236 |
Revenue
|
|||
| 70.69% | 75.52% | 74.15% | 75.28% | 77.42% | 74.86% | 74.14% | 74.80% | 72.58% | 73.05% |
Gross Margin
|
|||
| (7) | (9) | (12) | (13) | (34) | (17) | (4) | (21) | (42) | (39) |
EBT
|
|||
| (17.62%) | (19.58%) | (20.89%) | (17.48%) | (47.37%) | (17.73%) | (3.02%) | (14.33%) | (20.48%) | (16.58%) |
EBT Margin
|
|||
| (7) | (9) | (12) | (14) | (33) | (16) | 1 | (21) | (38) | (40) |
Net Income
|
|||
| 2 | 2 | 3 | 5 | 8 | 11 | 17 | 18 | 21 | 28 |
Depreciation
|
|||
| 21.39 | 11.36 | 4.58 | 4.96 | 3.94 | 5.09 | 5.91 | 6.56 | 8.87 | 10.07 |
Revenue/Sh
|
|||
| (3.77) | (6.12) | (0.96) | (0.94) | (1.82) | (0.84) | 0.06 | (0.92) | (1.64) | (1.69) |
Earnings/Sh
|
|||
| (0.64) | (1.80) | (1.24) | (1.22) | (1.03) | (0.68) | (1.05) | (1.19) | (1.17) | (0.21) |
Cash Flow/Sh
|
|||
| (2.73) | (1.63) | (0.43) | (0.83) | (0.63) | (0.83) | (0.48) | (0.84) | (0.62) | (0.47) |
Capex/Sh
|
|||
| (3.37) | (3.43) | (1.67) | (2.04) | (1.65) | (1.51) | (1.54) | (2.03) | (1.79) | (0.68) |
Free CF/Sh
|
|||
| 3.44 | 11.82 | 6.50 | 9.73 | 13.00 | 11.70 | 18.29 | 16.63 | 15.36 | 14.77 |
Book Value/Sh
|
|||
| 2 | 4 | 13 | 15 | 18 | 19 | 21 | 23 | 23 | 23 |
Shares
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1,024.25 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| 0.77 | 1.91 | 7.62 | 9.47 | 10.48 | 11.76 | 6.94 | 5.03 | 2.61 | 1.76 |
PS Ratio
|
|||
| 0.00 | 1.84 | 5.36 | 4.83 | 3.17 | 5.12 | 2.24 | 1.99 | 1.51 | 1.20 |
PB Ratio
|
|||
| 1.35 | 1.54 | 6.93 | 8.84 | 9.30 | 11.21 | 5.96 | 4.55 | 2.62 | 1.91 |
EV/Sales
|
|||
| (5.95) | (5.10) | (18.95) | (21.48) | (22.15) | (37.82) | (19.80) | (14.69) | (12.36) | (24.95) |
EV/FCF
|
|||
| (1) | (7) | (16) | (18) | (19) | (13) | (22) | (27) | (27) | (5) |
Op' Cash Flow
|
|||
| (5) | (7) | (5) | (12) | (11) | (16) | (10) | (19) | (14) | (11) |
Capex
|
|||
| (6) | (14) | (21) | (30) | (30) | (29) | (32) | (46) | (41) | (16) |
FCF
|
|||
| 14 | 60 | 88 | 114 | 123 | 104 | 196 | 185 | 203 | 210 |
Working Cap'
|
|||
| 18 | 25 | 21 | 26 | 1 | 1 | 1 | 10 | 72 | 97 |
Total Debt
|
|||
| 16 | (17) | (39) | (46) | (84) | (54) | (119) | (72) | 2 | 34 |
Net Debt
|
|||
| 6 | 47 | 82 | 142 | 235 | 225 | 379 | 377 | 355 | 347 |
Sh' Equity
|
|||
| (81.16%) | (41.65%) | (12.37%) | (9.33%) | (13.11%) | (5.21%) | 0.34% | (4.84%) | (8.29%) | (8.08%) |
ROA
|
|||
| (17.47%) | (13.32%) | (14.11%) | (5.88%) | (11.10%) | (6.57%) | (6.11%) | (5.49%) | (6.14%) | (6.44%) |
ROIC
|
|||
| 139.76% | 264.17% | (18.61%) | (12.25%) | (17.47%) | (7.07%) | 0.41% | (5.55%) | (10.34%) | (11.31%) |
ROE
|
|||
OrthoPediatrics Corp. peers in Medical Devices
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| SSII SS Innovations International, Inc. | $591.4M | 0.0× | Compare |
| DCTH Delcath Systems, Inc. | $558.0M | 1,560× | Compare |
| SENS Senseonics Holdings, Inc. | $546.7M | 0.0× | Compare |
| BWAY Brainsway Ltd. Sponsored ADR | $531.6M | 28.9× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| CERS Cerus Corporation | $524.0M | 0.0× | Compare |
| TCMD Tactile Systems Technology, Inc. | $518.5M | 20.7× | Compare |
| MASS 908 Devices Inc. | $492.7M | 0.0× | Compare |
| PACB Pacific Biosciences of California, Inc. | $484.9M | 0.0× | Compare |
OrthoPediatrics Corp. (KIDS) key facts
- OrthoPediatrics Corp. (KIDS) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- OrthoPediatrics Corp.’s revenue for fiscal 2025 (year ended December 2025) was $236.3 million, up 15.4% from fiscal 2024.
- As of September 25, 2026, KIDS traded at $22.55, a market capitalization of $591.1 million.
- Return on equity was −11.3% and debt-to-equity 0.28.
OrthoPediatrics Corp. (KIDS) Latest News
22 Sep
OrthoPediatrics announced the 1,000th Tibia Nail implantation using its Pediatric Nailing Platform (PNP). The system enables rigid tibial nails in pediatric patients and includes the 7mm cannulated rigid tibial nail—the smallest size—now offered in 7–12mm diameters. About 20% of nails implanted have been 7mm. The PNP Tibia features small access instruments, smaller nails, physeal-sparing fixation options, and supports both traditional and suprapatellar approaches. The Tibia system is currently available in five markets, with a European launch planned for 2027. Joe Hauser, President of Trauma & Deformity, highlighted rapid adoption and filling a critical void for pediatric implants. OrthoPediatrics markets 90+ systems across trauma/deformity, scoliosis, and sports medicine, distributing in the U.S. and over 75 countries. Milestone demonstrates strong early adoption of a pediatric-specific tibial nail platform and signals potential for expanded market and international growth.
11 Sep
OrthoPediatrics (KIDS) surpasses $70 million with raised financial guidance. Revenue milestone combined with higher guidance indicates improved financial outlook for the company.
25 Aug
OrthoPediatrics launches full commercial availability of its 3P Pediatric Plating Platform Hip System after more than 350 successful implantations. Full commercial launch of new pediatric hip plating system expands core product portfolio and supports revenue growth in orthopedics.
14 Aug
OrthoPediatrics reports record quarterly results driven by new product launches, marking an inflection point with strong revenue growth and improved market momentum. Record results powered by new products signal major growth acceleration and stronger competitive positioning for OrthoPediatrics.
11 Aug
OrthoPediatrics (KIDS) released its Q2 2026 earnings call transcript covering financial results, operations, and outlook. Earnings call provides financial metrics and guidance that may shift near-term investor views without major strategic shifts.
5 Aug
OrthoPediatrics Corp reported record revenue and EBITDA for Q2 2026. Record revenue and EBITDA signal strong financial results that can materially lift valuation and sentiment.
OrthoPediatrics Corp. (KIDS) released Q2 2026 earnings during its earnings call with updates on financial results and operations. Quarterly earnings results typically produce moderate short-term effects on stock price and outlook.
4 Aug
OrthoPediatrics Corp. reported second quarter 2026 financial results and raised its 2026 financial guidance. Raising 2026 guidance signals stronger expected performance that can shift investor sentiment and company trajectory.
OrthoPediatrics Corp. (KIDS) reported Q2 financial results and operational updates during its earnings call, including revenue performance, growth metrics, and management commentary on future outlook and initiatives. Q2 earnings call delivers financial metrics and strategic outlook that can shift near-term investor sentiment and valuation.
OrthoPediatrics Corp. (KIDS) posted a Q2 loss while exceeding revenue estimates. Q2 earnings showing a loss offset by revenue beat point to moderate effects on financial performance and near-term valuation.
24 Jun
OrthoPediatrics signs distribution agreement with OSSIO to deliver revolutionary orthopedic fixation technology to U.S. children’s hospitals nationwide. Distribution agreement expands pediatric access to new fixation technology and may improve competitive positioning.
25 May
Analysts reassess OrthoPediatrics (KIDS) growth prospects and valuation, shifting the investment narrative around the stock. Analyst reassessments of growth and valuation moderately shift market sentiment and company trajectory.
1 May
OrthoPediatrics Corp. (KIDS) reported strong revenue growth in Q1 2026 earnings call, highlighting robust financial performance and operational momentum. Strong Q1 2026 revenue growth indicates significant positive momentum for financial performance and investor sentiment.
30 Apr
OrthoPediatrics Corp. (KIDS) released Q1 2026 earnings call transcript detailing financial performance, revenue growth, product updates, and future outlook. Q1 2026 earnings transcript discloses financial results, guidance, and strategic initiatives that significantly shape investor expectations and market trajectory.
OrthoPediatrics Corp. reported first quarter 2026 financial results with revenue growth and profitability improvements, while raising full-year 2026 revenue and adjusted EBITDA guidance due to strong performance across segments. Raising full-year guidance signals strong momentum and financial health, likely driving positive investor sentiment and stock performance.
OrthoPediatrics Corp. expanded its specialty bracing portfolio by adding the TRAXIO Halo Gravity Traction System, designed for non-invasive spinal curve correction in pediatric patients with severe scoliosis and kyphosis. Addition of TRAXIO system represents a significant product launch enhancing OrthoPediatrics' bracing offerings and competitive edge in pediatric orthopedics.
OrthoPediatrics Corp. (KIDS) Q1 2026 earnings call summary covers quarterly financial results, operational updates, and forward guidance. Q1 2026 earnings details influence financial performance and investor sentiment moderately.
OrthoPediatrics Corp. (KIDS) released Q1 earnings call highlights covering financial results, revenue growth, product performance, and future guidance. Q1 earnings highlights influence financial performance and investor sentiment but are balanced by ongoing operations.
OrthoPediatrics Corp. (KIDS) reported first-quarter earnings, with key metrics providing insights into financial performance and operational health. Q1 earnings reports moderately impact financial metrics and investor sentiment without fundamentally altering long-term trajectory.
OrthoPediatrics Corp. (KIDS) reported a Q1 net loss but beat revenue estimates. Q1 revenue beat despite net loss moderately influences financial performance and investor sentiment.
16 Apr
OrthoPediatrics detailed clinic expansion plans, new product launches, and a goal for positive free cash flow by 2026 at the Needham Conference. Clinic expansions, new launches, and 2026 free cash flow target represent major strategic initiatives boosting growth and investor outlook.
24 Mar
Wall Street analysts predict a 51.12% upside for OrthoPediatrics Corp. (KIDS) stock. Analyst consensus of 51.12% upside targets could noticeably boost investor sentiment and short-term stock performance.
3 Mar
OrthoPediatrics Corp. (KIDS) upgraded to Buy rating by analysts, indicating positive outlook and potential stock price upside amid strong fundamentals and growth prospects. Analyst upgrade to Buy expected to moderately boost investor sentiment and short-term market performance without fundamentally altering long-term trajectory.
27 Feb
OrthoPediatrics Corp. (KIDS) released Q4 2025 earnings call summary detailing financial results, operational updates, and future guidance for the pediatric orthopedics specialist. Q4 earnings call summary includes financial performance and strategic outlook that significantly influence investor sentiment and company trajectory.
OrthoPediatrics Corp. (KIDS) reported strong revenue growth in Q4 2025 earnings call highlights. Strong revenue growth in Q4 2025 earnings directly boosts investor sentiment and company's market trajectory.
26 Feb
OrthoPediatrics Corp. (KIDS) Q4 earnings key metrics compared to estimates. Q4 earnings metrics versus estimates significantly impact financial performance outlook and investor sentiment.
OrthoPediatrics Corp. (KIDS) released Q4 earnings snapshot. Q4 earnings snapshot provides critical financial results that significantly impact stock price and investor outlook.
OrthoPediatrics Corp. (KIDS) reported fourth quarter and full year 2025 financial results. Quarterly and annual earnings reports significantly impact stock performance and investor sentiment.
OrthoPediatrics Corp. (KIDS) reported a Q4 net loss but exceeded revenue estimates. Q4 loss despite revenue beat indicates mixed financial results with moderate impact on performance and sentiment.
OrthoPediatrics Corp. (KIDS) Q4 earnings call highlights recent financial results, operational updates, and strategic outlook for the pediatric orthopedic device company. Q4 earnings call highlights reveal financial performance and guidance that moderately affect investor sentiment and near-term trajectory.